BIOMARIN PHARMACEUTICAL INC News on
HackerNoon and Around the Web

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. ...

Viatris and Biocon Biologics Launch Abevmy® (Bevacizumab), Their Third Oncology Biosimilar, in Canada

Published at May 19, 2022 by YAHOO!Finance

Biotech Stock News: Thiogenesis (TSXV: TTI) Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102

Published at May 18, 2022 by Investor ideas

Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102

Published at May 18, 2022 by Stockhouse

These were the biggest pharmaceutical deals in early 2022

Published at May 16, 2022 by Pharmaceutical Technology

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of “Buy” from Brokerages

Published at May 15, 2022 by ETF Daily News

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of “Buy” by Analysts

Published at May 15, 2022 by Defense World

Rare diseases - Drug Trial, Deals

Published at May 12, 2022 by The Pharma Letter

Rare diseases - Hematology, Pfizer

Published at May 11, 2022 by The Pharma Letter

Investment Analysts’ Recent Ratings Updates for BioMarin Pharmaceutical (BMRN)

Published at May 10, 2022 by Defense World

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

Published at May 09, 2022 by Seeking Alpha